207 related articles for article (PubMed ID: 29273955)
1. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma.
Vangangelt KMH; van Pelt GW; Engels CC; Putter H; Liefers GJ; Smit VTHBM; Tollenaar RAEM; Kuppen PJK; Mesker WE
Breast Cancer Res Treat; 2018 Apr; 168(3):601-612. PubMed ID: 29273955
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
Vangangelt KMH; Tollenaar LSA; van Pelt GW; de Kruijf EM; Dekker TJA; Kuppen PJK; Tollenaar RAEM; Mesker WE
Int J Cancer; 2018 Dec; 143(12):3194-3200. PubMed ID: 29978463
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients.
de Kruijf EM; Engels CC; van de Water W; Bastiaannet E; Smit VT; van de Velde CJ; Liefers GJ; Kuppen PJ
Breast Cancer Res Treat; 2013 Nov; 142(2):355-64. PubMed ID: 24197659
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC; Charehbili A; van de Velde CJ; Bastiaannet E; Sajet A; Putter H; van Vliet EA; van Vlierberghe RL; Smit VT; Bartlett JM; Seynaeve C; Liefers GJ; Kuppen PJ
Breast Cancer Res Treat; 2015 Feb; 149(3):587-96. PubMed ID: 25616355
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of tumour-stroma ratio in triple-negative breast cancer.
Moorman AM; Vink R; Heijmans HJ; van der Palen J; Kouwenhoven EA
Eur J Surg Oncol; 2012 Apr; 38(4):307-13. PubMed ID: 22264965
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of the Tumor-Stroma Ratio in Epithelial Ovarian Cancer.
Chen Y; Zhang L; Liu W; Liu X
Biomed Res Int; 2015; 2015():589301. PubMed ID: 26609529
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer.
Vangangelt KMH; Green AR; Heemskerk IMF; Cohen D; van Pelt GW; Sobral-Leite M; Schmidt MK; Putter H; Rakha EA; Tollenaar RAEM; Mesker WE
Int J Cancer; 2020 Apr; 146(8):2296-2304. PubMed ID: 31901133
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis.
Redondo M; García J; Villar E; Rodrigo I; Perea-Milla E; Serrano A; Morell M
Hum Pathol; 2003 Dec; 34(12):1283-9. PubMed ID: 14691914
[TBL] [Abstract][Full Text] [Related]
10. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients.
de Kruijf EM; van Nes JG; van de Velde CJ; Putter H; Smit VT; Liefers GJ; Kuppen PJ; Tollenaar RA; Mesker WE
Breast Cancer Res Treat; 2011 Feb; 125(3):687-96. PubMed ID: 20361254
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer.
de Kruijf EM; van Nes JG; Sajet A; Tummers QR; Putter H; Osanto S; Speetjens FM; Smit VT; Liefers GJ; van de Velde CJ; Kuppen PJ
Clin Cancer Res; 2010 Feb; 16(4):1272-80. PubMed ID: 20145162
[TBL] [Abstract][Full Text] [Related]
12. The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
Versluis MAC; Marchal S; Plat A; de Bock GH; van Hall T; de Bruyn M; Hollema H; Nijman HW
Eur J Cancer; 2017 Nov; 86():285-295. PubMed ID: 29059634
[TBL] [Abstract][Full Text] [Related]
13. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma.
Wang K; Ma W; Wang J; Yu L; Zhang X; Wang Z; Tan B; Wang N; Bai B; Yang S; Liu H; Zhu S; Cheng Y
J Thorac Oncol; 2012 Sep; 7(9):1457-61. PubMed ID: 22843085
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients.
Zeestraten EC; Reimers MS; Saadatmand S; Goossens-Beumer IJ; Dekker JW; Liefers GJ; van den Elsen PJ; van de Velde CJ; Kuppen PJ
Br J Cancer; 2014 Jan; 110(2):459-68. PubMed ID: 24196788
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study.
Reimers MS; Engels CC; Putter H; Morreau H; Liefers GJ; van de Velde CJ; Kuppen PJ
BMC Cancer; 2014 Jul; 14():486. PubMed ID: 24997850
[TBL] [Abstract][Full Text] [Related]
16. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy.
Mitra D; Horick NK; Brackett DG; Mouw KW; Hornick JL; Ferrone S; Hong TS; Mamon H; Clark JW; Parikh AR; Allen JN; Ryan DP; Ting DT; Deshpande V; Wo JY
Oncologist; 2019 Jun; 24(6):e275-e283. PubMed ID: 30755500
[TBL] [Abstract][Full Text] [Related]
17. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
[TBL] [Abstract][Full Text] [Related]
18. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.
de Kruijf EM; Sajet A; van Nes JG; Natanov R; Putter H; Smit VT; Liefers GJ; van den Elsen PJ; van de Velde CJ; Kuppen PJ
J Immunol; 2010 Dec; 185(12):7452-9. PubMed ID: 21057081
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854).
Dekker TJ; van de Velde CJ; van Pelt GW; Kroep JR; Julien JP; Smit VT; Tollenaar RA; Mesker WE
Breast Cancer Res Treat; 2013 Jun; 139(2):371-9. PubMed ID: 23709090
[TBL] [Abstract][Full Text] [Related]
20. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy.
Hansen TF; Kjær-Frifeldt S; Lindebjerg J; Rafaelsen SR; Jensen LH; Jakobsen A; Sørensen FB
Acta Oncol; 2018 Apr; 57(4):528-533. PubMed ID: 28980848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
